Back to results
US 2017/0304378 A1Published application
Modifying bacteriophage using beta-galactosidase as a selectable marker
AssigneePhico Therapeutics Ltd.
InventorsHeather FAIRHEAD, Adam WILKINSON, Neil ANDERSON, Katy PITTS, Anne BARNARD, Emmanuele SEVERI
Life of this patent
Estimating the term…
Abstract
A method for modifying the genome of a target phage is described. Compositions comprising such modified phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.
Claims20
1-19. (canceled)
A method for modifying the genome of a target phage, which comprises
- (a) providing a vector which contains a phage-targeting region which comprises a phage genome modifying element and encodes β-galactosidase or a subunit thereof;
- (b) mixing the vector with the target phage so as to modify the genome of the target phage;
- (c) propagating the resultant phage on a reporter host cell in the presence of a β-galactosidase substrate labelled with a reporter label under conditions to release the label in the presence of β-galactosidase activity;
- and
- (d) harvesting phage exhibiting β-galactosidase activity in the reporter host cell.
2 more elements
Dependencies are inferred from the claim text.